EVAX — Evaxion Biotech A/S Income Statement
0.000.00%
Last trade - 00:00- $2.20m
- $6.35m
- $3.34m
Annual income statement for Evaxion Biotech A/S, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.073 | 3.34 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 16.6 | 25.8 | 25.3 | 22.3 | 18.1 |
| Operating Profit | -16.6 | -25.8 | -25.3 | -22.2 | -14.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.6 | -24.7 | -23.9 | -22.9 | -11.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -15 | -24.5 | -23.2 | -22.1 | -10.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15 | -24.5 | -23.2 | -22.1 | -10.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15 | -24.5 | -23.2 | -22.1 | -10.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -39.6 | -62.9 | -48.9 | -40.5 | -0.985 |